FDA head admits controversy over Alzheimer’s drug decision impacted experts’ trust in the agencyApril 4, 2022Risk Management/SafetyRobert Califf, the new head of the Food and Drug Administration, admitted that the agency’s controversial approval of the Alzheimer’s drug Aduhelm has diminished its standing with experts.